RRRs of TSS50 at week 24 with pelabresib + ruxolitinib in MANIFEST arm 3 vs comparator arms: main analysis population (excluding patients with IPSS intermediate-1 risk). ∗Indicates that CIs and P values are calculated using the robust sandwich estimation of variance. RRR = (RR in Pela+Rux)/RR in comparator arm.